Good morning :)
$
₹
Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

SUPN

NASDAQ
Asset Logo

Supernus Pharmaceuticals Inc

SUPN

NASDAQ
$42.031.99% (+0.82)
$
₹
$42.031.99% (+0.82)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Mid Cap

With a market cap of $2.4B the stock is ranked 2025

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.44
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.92
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.47
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-13.23%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 4 analysts reports

Buy
3 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+43.81%

Earnings Growth

-10.81%

Rev. Growth

+22.95%

See Detailed Forecast

Company Profile

Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
43.09
43.09
1Y Return
61.07%
61.07%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
39.35
39.35
1Y Return
39.58%
39.58%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
117.69
117.69
1Y Return
68.06%
68.06%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
23.20
23.20
1Y Return
18.89%
18.89%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.23
25.23
1Y Return
0.1%
0.1%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 43.81% growth, versus a trailing 3-year CAGR of 20.98%.

2026
Current$42.07Baseline
Analyst Target - 1 year
Target$60.5+43.81%

All values in $

202220232024202520262027$36.17$46.30$56.42Target+43.81%
2026
Current$42.07Baseline
Analyst Target - 1 year
Target$60.5+43.81%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 22.95% growth, versus a trailing 3-year CAGR of 2.52%.

2025
Current$718.95Baseline
Forecast for Dec 2026
High$890+23.79%
Average$883.98+22.95%
Low$874.04+21.57%

All values in $ Million

202120222023202420252026579.77667.23607.52661.81718.95Low+21.57%Average+22.95%High+23.79%
2025
Current$718.95Baseline
Forecast for Dec 2026
High$890+23.79%
Average$883.98+22.95%
Low$874.04+21.57%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -10.81% growth, versus a trailing 3-year CAGR of 23.20%.

2025
Current$2.84Baseline
Forecast for Dec 2026
High$2.65-6.76%
Average$2.54-10.81%
Low$2.42-14.85%

All values in $

2021202220232024202520260.981.522.32.562.84Low-14.85%Average-10.81%High-6.76%
2025
Current$2.84Baseline
Forecast for Dec 2026
High$2.65-6.76%
Average$2.54-10.81%
Low$2.42-14.85%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

192.1
-45.1
211.5
-4.1
207.7
-2.2
219
-58.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue143.64168.32175.68174.15149.82165.45192.10211.57207.70219.05
Net Income0.1219.9138.4915.32-11.8222.49-45.11-4.10-2.29-58.37
Net Profit Margin0.08%11.83%21.91%8.80%-7.89%13.59%-23.48%-1.94%-1.10%-26.64%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Supernus Pharmaceuticals Inc -2.441.47
Eli Lilly and Company43.0930.281.13
Johnson & Johnson39.357.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SUPN with any stock or ETF
Compare SUPN with any stock or ETF
Comparing from
SUPN
LLY
JNJ
Loading...

Frequently asked questions

  1. Supernus Pharmaceuticals Inc (SUPN) share price today is $42.03 as of October 23, 2026 at 1:30 AM IST. The stock touched a day high of $42.03 and a day low of $40.75.

  2. Supernus Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol SUPN.

  3. Supernus Pharmaceuticals Inc's market capitalization is $2.4B as of October 23, 2026 at 1:30 AM IST.

  4. Supernus Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of October 22, 2026.

  5. Supernus Pharmaceuticals Inc's price-to-book (P/B) ratio is 2.44 as of October 22, 2026.

  6. Yes, You can buy Supernus Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Supernus Pharmaceuticals Inc shares in three steps: 1. Search Supernus Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Supernus Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Supernus Pharmaceuticals Inc (SUPN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.2379 shares at the current price of $42.03.

Loading...